Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Conference Call May 2, 2023 4:30 PM ET

Company Participants

Vincent Anzalone - Vice President, Investor Relations

Christopher Anzalone - President and Chief Executive Officer

Javier San Martin - Chief Medical Officer

James Hamilton - Chief, Discovery and Translational Medicine

Ken Myszkowski - Chief Financial Officer

Conference Call Participants

Maury Raycroft - Jefferies

Eliana Mural - UBS

Joel Beatty - Baird

Mani Foroohar - SVB

Mayank Mamtani - B. Riley Securities

Patrick Trucchio - HC Wainwright & Company

Keay Nakae - Chardan

Prakhar Agrawal - Cantor Fitzgerald

Luca Issi - RBC Capital

Madhu Kumar - Goldman Sachs

Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. [Operator Instructions] I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Vincent Anzalone

Thank you. Good afternoon everyone and thank you for joining us today to discuss Arrowhead’s results for its Fiscal 2023 Second Quarter Ended March 31, 2023. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our mid and later-stage clinical pipeline; Dr. James Hamilton, our Chief of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials.

In addition, Tracy Oliver, our Chief Commercial Officer and Patrick O’Brien, our Chief Operating Officer and General Counsel, will be available during the Q&A portion of the call. Before we begin, I would like to remind you that comments made during today’s call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q.

I’d now like to turn the call over to Chris Anzalone, President and CEO of the company. Chris?

Christopher Anzalone

Thanks, Vince. Good afternoon, everyone and thank you for joining us today. In 2017, we introduced our proprietary TRiM platform. We believe then that it could become an industry leading RNAi platform for hepatocyte focused therapies and importantly, one that could bring RNAi outside the liver. This was based entirely on our competence and the potential of the science